Goserelin ('Zoladex')--offering patients more choice in early breast cancer

Area of Science:

• Oncology
• Endocrinology

Background:

• Goserelin is a luteinizing hormone-releasing hormone analogue used to suppress ovarian estrogen production.
• It is administered as a 3.6 mg biodegradable, sustained-release depot via subcutaneous injection every 28 days.

Purpose of the Study:

• To evaluate the efficacy and tolerability of goserelin in premenopausal women with hormone-sensitive early breast cancer.
• To compare goserelin-based treatments with traditional chemotherapy regimens.

Main Methods:

• Clinical trials involving premenopausal women with early breast cancer.
• Goserelin administered alone or with tamoxifen, compared to cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy.
• Goserelin plus tamoxifen evaluated after cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) chemotherapy.

Main Results:

• Goserelin alone or with tamoxifen demonstrated at least equivalent efficacy to CMF chemotherapy.
• Goserelin plus tamoxifen after CAF chemotherapy improved disease-free survival compared to CAF alone.
• Goserelin was well tolerated with significantly less acute toxicity than cytotoxic chemotherapy.

Conclusions:

• Goserelin is an effective treatment option for premenopausal women with hormone-sensitive early breast cancer.
• It offers a viable alternative to chemotherapy, associated with improved quality of life and reduced toxicity.
• Patient involvement in treatment decisions, informed by benefits and risks, is crucial.